Analysts Set Orthofix Medical Inc. (NASDAQ:OFIX) PT at $18.25

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have been assigned an average recommendation of “Hold” from the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $18.25.

A number of research analysts recently issued reports on OFIX shares. TD Cowen started coverage on Orthofix Medical in a research report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price objective for the company. Barrington Research cut their target price on Orthofix Medical from $18.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen raised shares of Orthofix Medical from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group lowered their price target on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a report on Thursday, January 22nd.

Insider Buying and Selling at Orthofix Medical

In other news, CEO Massimo Calafiore sold 9,797 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.21, for a total transaction of $149,012.37. Following the completion of the transaction, the chief executive officer directly owned 217,237 shares in the company, valued at approximately $3,304,174.77. The trade was a 4.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Engine Capital Management, Lp bought 13,061 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average price of $12.96 per share, for a total transaction of $169,270.56. Following the completion of the transaction, the insider owned 3,673,092 shares in the company, valued at $47,603,272.32. This trade represents a 0.36% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have sold 24,270 shares of company stock worth $370,958. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Orthofix Medical

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its stake in shares of Orthofix Medical by 99.0% in the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock worth $28,000 after buying an additional 955 shares in the last quarter. State of Alaska Department of Revenue bought a new position in Orthofix Medical during the third quarter valued at about $30,000. Kestra Advisory Services LLC bought a new position in Orthofix Medical during the fourth quarter valued at about $56,000. Strs Ohio acquired a new position in Orthofix Medical during the first quarter worth about $150,000. Finally, Mackenzie Financial Corp bought a new stake in Orthofix Medical in the third quarter worth about $148,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Orthofix Medical Stock Performance

Orthofix Medical stock traded up $0.05 during mid-day trading on Friday, reaching $12.62. The company’s stock had a trading volume of 304,654 shares, compared to its average volume of 300,840. The firm has a market cap of $506.57 million, a price-to-earnings ratio of -5.39 and a beta of 0.75. The business has a 50 day moving average price of $13.85 and a 200-day moving average price of $14.66. The company has a current ratio of 2.45, a quick ratio of 1.43 and a debt-to-equity ratio of 0.39. Orthofix Medical has a twelve month low of $10.24 and a twelve month high of $17.28.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.50). Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%.The business had revenue of $219.91 million for the quarter, compared to analyst estimates of $218.72 million. Sell-side analysts predict that Orthofix Medical will post -2.81 EPS for the current fiscal year.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.